Biological and Social Determinants of Hypertension Severity Before vs After Intracerebral Hemorrhage.

Autor:	Abramson JR; From the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA., Castello JP; From the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA., Keins S; From the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA., Kourkoulis C; From the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA., Rodriguez-Torres A; From the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA., Myserlis EP; From the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA., Alabsi H; From the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA., Warren AD; From the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA., Henry JQA; From the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA., Gurol ME; From the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA., Viswanathan A; From the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA., Greenberg SM; From the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA., Towfighi A; From the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA., Skolarus L; From the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA., Anderson CD; From the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA., Rosand J; From the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA., Biffi A; From the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA. abiffi@mgh.harvard.edu.
Jazyk:	angličtina
Zdroj:	Neurology [Neurology] 2022 Mar 29; Vol. 98 (13), pp. e1349-e1360. Date of Electronic Publication: 2022 Feb 07.
DOI:	10.1212/WNL.0000000000200003
Abstrakt:	Background and Objectives: Although blood pressure (BP) control is considered the most effective measure to prevent functional decline after intracerebral hemorrhage (ICH), fewer than half of survivors achieve treatment goals. We hypothesized that long-term (i.e., prehemorrhage) hypertension severity may be a crucial factor in explaining poor BP control after ICH. We investigated changes in hypertension severity after vs before ICH using latent class analysis (LCA) and identified patient characteristics predictive of individuals' BP trajectories. Methods: We analyzed data for ICH survivors enrolled in a study conducted at Massachusetts General Hospital (MGH) from 2002 to 2019 in Boston, a high-resource setting with near-universal medical insurance coverage. We captured BP measurements in the 12 months preceding and following the acute ICH hospitalization. Using LCA, we identified patient groups (classes) based on changes in hypertension severity over time in an unbiased manner. We then created multinomial logistic regression models to identify patient factors associated with these classes. Results: Among 336 participants, the average age was 74.4 years, 166 (49%) were male, and 288 (86%) self-reported White race/ethnicity. LCA identified 3 patient classes, corresponding to minimal (n = 114, 34%), intermediate (n = 128, 38%), and substantial (n = 94, 28%) improvement in hypertension severity after vs before ICH. Survivors with undertreated (relative risk ratio [RRR] 0.05, 95% CI 0.01-0.23) or resistant (RRR 0.03, 95% CI 0.01-0.06) hypertension before ICH were less likely to experience substantial improvement afterwards. Residents of high-income neighborhoods were more likely to experience substantial improvement (RRR 1.14 per $10,000, 95% CI 1.02-1.28). Black, Hispanic, and Asian participants with uncontrolled hypertension before ICH were more likely to experience minimal improvement after hemorrhagic stroke (interaction p < 0.001). Discussion: Most ICH survivors do not display consistent improvement in hypertension severity after hemorrhagic stroke. BP control after ICH is profoundly influenced by patient characteristics predating the hemorrhage, chiefly prestroke hypertension severity and socioeconomic status. Neighborhood income was associated with hypertension severity after ICH in a high-resource setting with near-universal health care coverage. These findings likely contribute to previously documented racial/ethnic disparities in BP control and clinical outcomes following ICH. (© 2022 American Academy of Neurology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu